These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24318568)

  • 1. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.
    Saxena A; Bester L; Shan L; Perera M; Gibbs P; Meteling B; Morris DL
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):537-47. PubMed ID: 24318568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
    Saxena A; Meteling B; Kapoor J; Golani S; Morris DL; Bester L
    Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 radioembolization is a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases: further evidence in support of a new treatment paradigm.
    Hickey R; Lewandowski R; Salem R
    Ann Surg Oncol; 2015 Mar; 22(3):706-7. PubMed ID: 25358665
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
    Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
    J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.
    Damm R; Seidensticker R; Ulrich G; Breier L; Steffen IG; Seidensticker M; Garlipp B; Mohnike K; Pech M; Amthauer H; Ricke J
    BMC Cancer; 2016 Jul; 16():509. PubMed ID: 27439702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
    Saxena A; Kapoor J; Meteling B; Morris DL; Bester L
    Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
    Maleux G; Deroose C; Laenen A; Verslype C; Heye S; Haustermans K; De Hertogh G; Sagaert X; Topal B; Aerts R; Prenen H; Vanbeckevoort D; Vandecaveye V; Van Cutsem E
    Acta Oncol; 2016; 55(4):486-95. PubMed ID: 26625262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM).
    Dhir M; Zenati MS; Jones HL; Bartlett DL; Choudry MHA; Pingpank JF; Holtzman MP; Bahary N; Hogg ME; Zeh HJ; Geller DA; Wallis Marsh J; Tsung A; Zureikat AH
    Ann Surg Oncol; 2018 Feb; 25(2):550-557. PubMed ID: 29181682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 10. Robust evidence for long-term survival with
    Jakobs TF; Paprottka KJ; Raeßler F; Strobl F; Lehner S; Ilhan H; Trumm CG; Fendler WP; Sommer W; Paprottka PM
    Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
    Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
    Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
    Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
    Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases.
    Jia Z; Paz-Fumagalli R; Frey GT; Sella DM; McKinney JM; Wang W
    Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):899-905. PubMed ID: 31104533
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study.
    Topcuoglu OM; Orhan T; Gormez A; Alan N
    Br J Radiol; 2024 Jun; 97(1159):1255-1260. PubMed ID: 38730551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-Based Integration of Yttrium-90 Radioembolization in the Contemporary Management of Hepatic Metastases from Colorectal Cancer.
    Wang DS; Louie JD; Sze DY
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):74-80. PubMed ID: 31079714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study.
    Haber Z; Lee EW; Price M; Wainberg Z; Hecht JR; Sayre J; Padia SA
    Acad Radiol; 2021 Nov; 28 Suppl 1():S210-S217. PubMed ID: 34099386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?
    Sangha BS; Nimeiri H; Hickey R; Salem R; Lewandowski RJ
    Curr Treat Options Oncol; 2016 Jun; 17(6):26. PubMed ID: 27098532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases.
    Chua TC; Bester L; Saxena A; Morris DL
    J Cancer Res Clin Oncol; 2011 May; 137(5):865-73. PubMed ID: 20859640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver metastases from colorectal cancer: radioembolization with systemic therapy.
    Nicolay NH; Berry DP; Sharma RA
    Nat Rev Clin Oncol; 2009 Dec; 6(12):687-97. PubMed ID: 19884901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.